Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Avanos Medical, Inc. $AVNS

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Avanos Medical, Inc. (NYSE:AVNS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,330 shares of the company’s stock, valued at approximately $126,000.

A number of other hedge funds also recently bought and sold shares of AVNS. US Bancorp DE boosted its position in Avanos Medical by 7.7% in the first quarter. US Bancorp DE now owns 15,184 shares of the company’s stock worth $218,000 after purchasing an additional 1,091 shares during the last quarter. Cary Street Partners Financial LLC purchased a new stake in shares of Avanos Medical during the 1st quarter valued at about $226,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Avanos Medical by 32.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 608,635 shares of the company’s stock worth $8,722,000 after purchasing an additional 148,619 shares during the period. Entropy Technologies LP purchased a new position in shares of Avanos Medical in the first quarter worth approximately $254,000. Finally, Nuveen LLC purchased a new position in shares of Avanos Medical in the first quarter worth approximately $1,839,000. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Avanos Medical in a research report on Tuesday. Finally, Zacks Research raised Avanos Medical to a “hold” rating in a report on Tuesday, August 12th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Avanos Medical has an average rating of “Reduce”.

Avanos Medical Stock Down 0.8%

AVNS opened at $11.74 on Friday. The stock has a market cap of $544.97 million, a price-to-earnings ratio of -1.15 and a beta of 1.19. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. The firm’s fifty day moving average is $11.48 and its 200 day moving average is $11.80. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $19.91.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. The business had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. On average, sell-side analysts forecast that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Avanos Medical news, SVP Kerr Holbrook sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the transaction, the senior vice president directly owned 83,860 shares in the company, valued at $922,460. This represents a 15.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.